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Introduction  1 
 2 
Our preference for ‘attractive’ faces is well-documented, and is present in infants 3 
from birth1. The preference continues through adulthood, with attractive individuals 4 
experiencing greater social2, occupational3, and dating4 success than their less 5 
attractive counterparts. Despite individual differences in the specifics of the faces that 6 
we each find attractive, we are generally consistent in identifying attractiveness5. 7 
According to evolutionary psychologists, our preference for attractive faces serves an 8 
adaptive function: encouraging us to choose high-quality mates for the propagation of 9 
our genes. We show consistent preferences, for example, for cues to good health in 10 
the face (e.g. symmetry6 and averageness7). We also tend to perceive younger adult 11 
faces as more attractive than older faces, perhaps due to the link between youth and 12 
fertility8.  13 
 14 
Given the value we attribute to attractiveness and a youthful appearance, it is no 15 
surprise that facial rejuvenation approaches target signs of aging9. During aging, 16 
upper facial regions lose collagen and elasticity, causing skin sagging10. Repetitive 17 
muscular contraction leads to the development of upper dynamic facial lines, 18 
predominantly in the glabellar (“frown”), forehead (“raise eyebrows”) and crows feet 19 
(“big smile”) areas11. These areas, then, have been the target of rejuvenation 20 
techniques, among which Botulinum Toxin Type A (BoNT-A) is the most popular 21 
non-surgical treatment worldwide (Fink & Prager, 2014). This non-invasive injectable 22 
acts as a muscle relaxant, blocking the release of the neurotransmitter acetylcholine; a 23 
key messenger for muscle contractions12, so reducing or eradicating the appearance of 24 
upper dynamic facial lines for 8 to 12 weeks, and can also be used to correct 25 
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asymmetry and raise the brow (Dayan, Arkins, Patel & Gal, 2010). The popularity of 26 
BoNT-A treatments is evidenced by 80-90% of patients reporting satisfaction with 27 
their treatment, and many stating they would recommend the treatment to others 28 
(Sommer et al, 2003; see Fagien & Carruthers, 2008 for a comprehensive review).  29 
 30 
In addition to satisfaction with appearance post-treatment, there is a growing body of 31 
evidence that treatment with BoNT-A results in improved psychological outcomes, 32 
such as self-esteem17. Lewis and Bowler18, for example, report that patients treated 33 
with BoNT-A had significantly better mood than those treated with another cosmetic 34 
procedure. According to Jandhyala19, however, the most powerful way to assess the 35 
effect of BoNT-A on patient psychological wellbeing is to compare validated 36 
measures before and after treatment. Dayan et al14, for example, in their double blind, 37 
randomized, placebo-controlled study demonstrated that participants treated with 38 
BoNT-A showed a significant improvement in self-reported measures on standardized 39 
scales of quality of life and self-esteem, compared to those in a placebo group (i.e. 40 
injected with saline).  41 
 42 
Dayan et al14 argue that the psychological effects of BoNT-A exist for one of two 43 
reasons: (1) the physical improvement of patient’s wrinkle concerns contributes to 44 
self-esteem, or (2) more favorable treatment from others, as a result of BoNT-A, 45 
encourages greater self-esteem. Both of these seem plausible, particularly in light of 46 
the human preferences for attractive faces discussed above. Thus, perhaps the effects 47 
of BoNT-A involve an interaction between both mechanisms, wherein a patient 48 
treated with BoNT-A experiences increased satisfaction with their appearance directly 49 
which, in turn (and in combination with putative direct effects of BoNT-A on 50 
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attractiveness), causes them to interact more positively with others, leading them to be 51 
perceived as more attractive. This attractiveness preference may then encourage more 52 
favourable treatment towards the BoNT-A patient, reinforcing the boost to self-53 
esteem. Subjective patient reports support this assumption; with patients revealing 54 
that they felt others treated them more favourably following BoNT-A treatment20.  55 
Indeed, there is even evidence that faces treated with BoNT-A are perceived as more 56 
positive for predicted academic performance, occupation, dating and athletic success, 57 
and attractiveness20. 58 
 59 
To summarise, BoNT-A improves objectively rated facial attractiveness13,20 which 60 
may contribute to BoNT-A patients’ improved psychological wellbeing following 61 
treatment. However, no previous work has assessed the same patient sample (i.e. 62 
patient self-esteem and other’s perception of that patient post-BoNT-A) in order to 63 
make these inferences. Our study, then, is a controlled experiment using validated 64 
psychological measures and pre- and post-treatment comparison to test the following 65 
predictions: (1) treatment with BoNT-A will improve psychological wellbeing; (2) 66 
treatment with BoNT-A will improve attractiveness rated by self and others; (3) 67 
attrativeness rated by self and others will mediate the effects of BoNT-A on 68 
psychological wellbeing.  69 
 70 
We tested the predictions in a sample of female participants using a repeated-71 
measures design. We measured self-esteem, satisfaction with life, and self-rated 72 
attractiveness prior to, and 4 weeks (+/- 3 days) post, BoNT-A treatment. We took 73 
facial photographs at both time points, and these were rated for attractiveness by 74 
participants who were unfamiliar with those in the photographs.  75 
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 76 
Methods  77 
 78 
Participants  79 
We recruited 32 female participants aged 27 to 72 (mean = 41.66, SD = 12.48) from 80 
Fresh Inc MediSpa, Invergowrie, Scotland. Volunteers were denied participation if 81 
they had a medical condition that would contraindicate BoNT-A treatment, the 82 
presenting lines were not suitable for BoNT-A treatment, or they had previously 83 
received a treatment that would interfere with BoNT-A’s treatment outcome. For 7 84 
participants (21.88%) this was their first treatment with BoNT-A. The remainder 85 
(78.12%) had not been treated in the past 6 months.  86 
 87 
Materials  88 
Participants receiving BoNT-A treatment completed standardised measures of self-89 
esteem, satisfaction with life, and self-rated attractiveness.  90 
 91 
Self-esteem was assessed using Rosenberg’s21 Self-Esteem Questionnaire, which 92 
includes statements such as ‘On the whole, I am satisfied with myself’ and provides a 93 
measure of the extent to which an individual values themselves.  94 
 95 
Satisfaction with Life was measured using Deiner’s Satisfaction with Life 96 
Questionnaire22, which is a five-item questionnaire, including items such as ‘In most 97 
ways my life is close to my ideal’.  98 
 99 
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To assess self-rated attractiveness before and after treatment, patients were simply 100 
asked ‘How attractive do you perceive yourself to be?’ Responses were scored on a 101 
five-point scale, ranging from unattractive (scored as 1) to attractive (scored as 5). 102 
This is standard in the facial attractiveness literaturee.g. 5.  103 
 104 
Facial attractiveness  105 
Facial images were collected using an iPhone 5S camera, at 1m distance from the 106 
patient, against a white background and under standardised lighting. We instructed 107 
participants to wear consistent makeup and hairstyles for photographs taken pre- and 108 
post-treatment, and to maintain a neutral facial expression. Facial images were 109 
masked using Psychomorph software23 to disguise clothes, hair, and jewellery. Thirty-110 
one participants provided consent for their photos to be rated for attractiveness pre- 111 
and post-treatment.  112 
 113 
Raters were 22 men and 78 women (mean age = 28.51, S.D. = 11.39) recruited via 114 
social media from the Universities of Liverpool and Nottingham Trent, in order to 115 
avoid familiarity with participants in the BoNT-A trial. We provided participants with 116 
a link which allocated them at random to rate either the pre-treatment or post-117 
treatment faces. There were 50 raters for each set of images. Faces were presented in 118 
random order via an online survey, and raters were asked to rate each face from 1 119 
(very unattractive) to 7 (very attractive). Raters were naïve to the purpose of the study 120 
and were not informed that either condition consisted of post-BoNT-A images. They 121 
were fully debriefed at the end of the study.  122 
 123 
Procedure 124 
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 125 
The study received full approval from the University of Dundee Research Ethics 126 
Committee and the owner and manager of Fresh Inc MediSpa.  127 
 128 
In-clinic appointments were scheduled for patients who expressed an interest in 129 
participating in the study. Patients were required to attend the clinic on three 130 
occasions. Session 1: We presented potential participants the clinic’s ‘General 131 
Consultation Questionnaire’ and Azzalure’sTM Treatment Consent Form in 132 
accordance with clinic protocol. Upon completion, patients were seen by the in-house 133 
General Practitioner (GP) to assess their medical fitness for BoNT-A treatment. Once 134 
GP approval was given, we provided participants with a Participant Information Sheet 135 
and Consent Form, and obtained consent from the GP and Senior Practitioner. 136 
Participants completed the psychological wellbeing measures followed by facial 137 
photography. We then took them to the treatment room for the BoNT-A therapy. To 138 
ensure consistency of treatment procedure, the senior practitioner conducted all 139 
BoNT-A treatments. Each vial containing 125 speywood units of Azzalure 140 
(Galderma) was diluted with 0.63ml of Bacteriostatic Saline, following reconstitution 141 
directions as instructed in Azzalure’s manual24. There was no standardized treatment 142 
protocol, and injections depended upon participants’ muscle activity, depth of lines 143 
and the areas treated. Therefore, a record was kept of the number of areas treated, and 144 
the units injected, for each participant. Treatment areas were limited to the glabellar 145 
area, forehead and crow’s feet.  146 
 147 
Session 2: Participants returned to the clinic 2-weeks post BoNT-A treatment for a 148 
scheduled review. Any further injections, if required, were administered at this stage.  149 
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 150 
Session 3: Patients returned to the clinic 4-weeks (+/- 3 days) after the initial BoNT-A 151 
treatment. Participants completed measures of psychological wellbeing and had their 152 
photograph taken as for Session 1. Participants were then fully debriefed.  153 
 154 
Results  155 
 156 
Table 1 Means (and standard deviations) for all variables, and Spearman’s correlation 157 
coefficients for relationships between all variables. 158 
 159 
Variable 1. 2. 3. 4. 5. 6. Mean (SD) 
1. Age       41.66 (12.48) 
2. Units  0.06      138.88 (42.6) 
3. Areas treated -.03 .68*     2.53 (0.67) 
4. Self-esteem change .13 .01 -.04    4.91 (4.35) 
5. SWL change .08 -.11 -.12 .59*   6 (4.98) 
6. Self-rated 
attractiveness change 
.09 .07 .1 .7* .59*  1.28 (1.11) 
7. Other-rated 
attractiveness change 
-0.25 0.01 0.14 0.24 0.09 0.1 1.25 (0.42) 
* p < 0.001   
 160 
All variables were within specified parameters of normality, so parametric analyses 161 
were employed. As age, number of areas treated, and number of units injected were 162 
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not correlated with the variables of interest (all p > 0.09), we did not include these in 163 
further analyses.  164 
 165 
Does treatment with BoNT-A improve psychological wellbeing? 166 
 167 
In bivariate regression models, a treatment level dummy variable (0 = pre-treatment, 1 168 
= post-treatment) was found to significantly predict self-esteem (Adj R2 = 0.24, F(1, 169 
62) = 20.4, p < 0.001, β = 0.5, p < 0.001) and satisfaction with life (Adj R2 = 0.22, F(1, 170 
62) = 18.27, p < 0.001, β = 0.48, p < 0.001), such that both were significantly higher 171 
post-treatment. Figure 1 shows the significant effects of treatment on self-esteem and 172 
satisfaction with life. 173 
 174 
Figure 1 about here. 175 
 176 
Does treatment with BoNT-A improve attractiveness rated by self and others? 177 
 178 
In bivariate regression models, a treatment level dummy variable (0 = pre-treatment, 1 179 
= post-treatment) was found to significantly predict attractiveness rated by self (Adj 180 
R2 = 0.36, F(1, 62) = 35.72, p < 0.001, β = 0.61, p < 0.001) and attractiveness rated by 181 
others (Adj R2 = 0.49, F(1, 60) = 58.63, p < 0.001, β = 0.7, p < 0.001), such that both 182 
were significantly higher post-treatment. Figure 2 shows the significant effects of 183 
treatment on attractiveness rated by both self and others. 184 
 185 
Figure 2 about here. 186 
 187 
  9 
Does attractiveness mediate the effects of treatment with BoNT-A on psychological 188 
wellbeing? 189 
As described above, treatment significantly predicted psychological wellbeing and 190 
attractiveness. In order to determine whether attractiveness mediated the effects of 191 
treatment on psychological wellbeing, we first tested for bivariate relationships 192 
between measures of psychological wellbeing and attractiveness. Self-rated 193 
attractiveness significantly predicted self-esteem (Adj R2 = 0.46, F(1, 62) = 54.85, p < 194 
0.001, β = 0.69, p < 0.001) and satisfaction with life (Adj R2 = 0.22, F(1, 62) = 18.95, 195 
p < 0.001, β = 0.48, p < 0.001), and attractiveness rated by others significantly 196 
predicted self-esteem (Adj R2 = 0.2, F(1, 60) = 16.56, p < 0.001, β = 0.47, p < 0.001) 197 
and satisfaction with life (Adj R2 = 0.14, F(1, 60) = 11.24, p < 0.001, β = 0.4, p = 198 
0.001). In all cases, higher attractiveness ratings were associated with more positive 199 
psychological wellbeing.  200 
 201 
When self-rated attractiveness and treatment level were entered as simultaneous 202 
predictors in the model, with self-esteem as the criterion (Adj R2 = 0.46, F(1, 61) = 203 
28.19, p < 0.001), treatment level lost significance (β = 0.13, p = 0.261) and self-rated 204 
attractiveness maintained significance (β = 0.61, p < 0.001). Therefore, self-rated 205 
attractiveness mediated the effect of treatment on self-esteem. Figure 3 shows this 206 
mediating relationship. 207 
 208 
Figure 3 about here. 209 
 210 
When attractiveness rated by others and treatment level were entered as simultaneous 211 
predictors in the model, with self-esteem as the criterion (Adj R2 = 0.26, F(1, 59) = 212 
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11.93, p < 0.001), treatment level maintained significance (β = 0.38, p = 0.018) and 213 
attractiveness rated by others lost significance (β = 0.2, p = 0.199). Therefore, 214 
attractiveness rated by others did not mediate the effect of treatment on self-esteem.  215 
 216 
When attractiveness rated by self and treatment level were entered as simultaneous 217 
predictors in the model, with satisfaction with life as the criterion (Adj R2 = 0.26, F(1, 218 
61) = 12.32, p < 0.001), treatment level maintained significance (β = 0.29, p = 0.036), 219 
and so too did self-rated attractiveness (β = 0.31, p = 0.027). Therefore, attractiveness 220 
rated by self did not mediate the effect of treatment on satisfaction with life.  221 
 222 
Finally, when attractiveness rated by others and treatment level were entered as 223 
simultaneous predictors in the model, with satisfaction with life as the criterion (Adj 224 
R2 = 0.21, F(1, 59) = 9, p < 0.001), treatment level maintained significance (β = 0.39, 225 
p = 0.019), and attractiveness rated by others lost significance (β = 0.39, p = 0.44). 226 
Therefore, attractiveness rated by others did not mediate the effect of treatment on 227 
satisfaction with life.  228 
 229 
Table 2 summarises all results. 230 
 231 
Table 2 about here 232 
Discussion  233 
 234 
Here we have shown that treatment with BoNT-A results in significant improvements 235 
to psychological wellbeing (self-esteem and satisfaction with life) and attractiveness 236 
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(as rated by self and others), and that the effects of treatment on self-esteem occur via 237 
the effects of treatment on attractiveness rated by self.  238 
 239 
Our results are consistent with previous work which has reported benefits of BoNT-A 240 
for of psychological wellbeinge.g.14. Our study, however, was also able to detect 241 
positive effects on wellbeing that extended those beyond quality of life measures 242 
specific to cosmetic treatment, and demonstrate that treatment with BoNT-A has 243 
benefits on life satisfaction more broadly. Furthermore, our study was the first to test 244 
the effects of BoNT-A on attractiveness rated by self and others, and to determine 245 
whether it was these effects which, in turn, accounted for the positive influence of 246 
treatment on psychological wellbeing.  247 
 248 
As we argued earlier, there are 2 pathways by which effects of BoNT-A on 249 
attractiveness may be translated into effects on psychological wellbeing. In the first, 250 
individuals who are perceived as ‘attractive’ may receive more favourable treatment 251 
from others which, in turn, may provide an intermediate ‘mediating’ step between 252 
treatment with BoNT-A and psychological wellbeing: if treatment causes others to 253 
perceive the individual as more attractive and, therefore, treat them more favourably 254 
in social interactions, this may lead to improved psychological wellbeing20. Our 255 
analyses, however, failed to detect this effect, as attractiveness rated by others did not 256 
mediate relationships between treatment and self-esteem or satisfaction with life. In 257 
the second, the positive effects of treatment with BoNT-A on self-rated attractiveness 258 
are responsible for the positive effects of treatment on psychological wellbeing: given 259 
the value placed on ‘attractiveness’, feeling more attractive is predicted to boost an 260 
individual’s psychological wellbeing. We found support for this as self-rated 261 
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attractiveness mediated the effects of treatment on self-esteem. In other words, 262 
treatment improves self-rated attractiveness which, in turn, improves self-esteem. We 263 
did not find a mediating role of self-rated attractiveness in the effect of treatment on 264 
satisfaction with life, and it may be that this variable is too broad and comprised of 265 
too much that is external to, and unaffected by, physical appearance for such effects to 266 
be detected. Indeed, Dayan et al20 argue that a fundamental facet of self-esteem is an 267 
individual’s attitude to their own aesthetic appearance. If they are dissatisfied with 268 
how they look, or consider themself unattractive, they are more likely to possess low 269 
self-esteem. Our results support this, and show that treatment with BoNT-A have a 270 
positive influence on self-perceived attractiveness and, in turn, self-esteem. 271 
 272 
Results of the current study are encouraging for the field of aesthetic medicine, 273 
highlighting the success of BoNT-A for the improvement of psychological wellbeing. 274 
We acknowledge, however, that a placebo-controlled double blind methodology 275 
would provide a more rigorous test of our predictions. We suggest that future work 276 
should test the pathways we have identified here in clinical populations that are 277 
characterized by low self-esteem (e.g. eating disorders and depression).  278 
 279 
 280 
In conclusion, we have demonstrated that treatment with BoNT-A results in 281 
significant improvements to psychological wellbeing (self-esteem and satisfaction 282 
with life) and attractiveness (as rated by self and others), and that the effects of 283 
treatment on self-esteem occur via the effects of treatment on self-rated attractiveness. 284 
We conclude that treatment with BoNT-A has benefits for psychological wellbeing 285 
and facial appearance, both as perceived by the self and by others. 286 
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Figure 1 Showing mean self-esteem (left) and satisfaction with life (right) in 380 
participants pre- and post-treatment (error bars are +- 1 SE) 381 
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 382 
Figure 2 Showing mean self-rated (left) and other-rated (right) attractiveness in 383 
participants pre- and post-treatment (error bars are +- 1 SE) 384 
 385 
Figure 3 Mediation model showing beta coefficients for treatment with BoNT-A and 386 
self-rated attractiveness in predicting self-esteem. The c path represents the effect of 387 
treatment on self-esteem without the mediator (total effect) and the c’ path is the 388 
effect of treatment on sefl-esteem after accounting for the mediator (direct effect). *p 389 
< 0.01. 390 
 391 
 392 
